Category Archives: Cell Biology

UConn faculty reflect on surveillance testing efforts, look to the future – UConn Daily Campus

Rachel ONeill, professor of molecular and cell biology, Kendra Maas, facility scientist at the University of Connecticuts MARS and Suzanne Onorato, executive director of student health and wellness, touched on the success of UConns fall testing efforts and discussed their hopes and plans for the spring.

ONeill began by providing a brief description of why the saliva testing effort is valuable. In essence, she said the pooled testing efforts were done to more efficiently utilize resources while working with UConns low positivity rate.

The overarching goal of this whole collective program is to reduce costs significantly and save critical, clinical-level tests for symptomatic or high-positivity rate areas, ONeill said. Right now, were at a really low positivity rate, so its an ideal approach to take.

Maas further emphasized UConns successful numbers so far. She said this reflects students general willingness to follow CDC guidelines and regulations.

I can say that, so far, the surveillance screening that we have done has been remarkably low positives, and thats been reflected by follow-up point of care tests and that percentage that were seeing at UConn, which is lower than the state, so we can say that students are doing a good job of following those CDC guidelines, Maas said.

In addition to the group testing being done, Onorato wanted to draw attention to Dr. Maass work with wastewater sampling. Onorato said they hope to expand this test to get even more accurate readings of where the COVID-19 increase may have originated.

When a particular wastewater site begins to have an increase in the presence of COVID, we then deploy pooled sampling to screen those students who reside in that area, Onorato said. This then allows for us to locate the positive cases early on and allows for rapid containment of the spread of COVID. We would like to continue to both create more local sources for wastewater testing in order to get even closer to the source with our pooled sampling.

ONeill said one of the major challenges they have faced so far has been clearly communicating everything to students. She said it is their responsibility to convey information to students well.

Weve actually done collaborations with amazing teams on campus who are going to help us translate this information and make it publicly available because I think it is our responsibility to translate that information and allow people to know this is the level when you should be worried, and this is more informational and we need to be keeping track, ONeill said.

ONeill also said it was important to note the expanse of the program and the amount of collaboration it has required. In particular, she noted the work done by UConn facilities to help Dr. Maas install her wastewater monitoring systems.

This project has been collaborative and huge. Its involved many, many groups on campus who have been incredible at stepping up to try to protect the safety of the students, ONeill said. Facilities have been right there every step of the way helping Kendra put these wastewater monitoring systems in place. Its just been absolutely incredible to watch.

Maas wanted to draw attention to the work being done by the student body as well. She said she has several UConn students, both graduate and undergraduate, assisting with her work.

All of the technicians who are doing this are students, Maas said. I have three masters grad students who do most of the lab work, and then I have a couple of undergrads who are helping collect samples and distribute tubing. This is all students.

Onorato spoke about future testing plans and the potential expansion of surveillance testing. She said this would likely be done in addition to educational efforts that showed proper strategies for the UConn student body regarding COVID-19.

ISG is also interested in expanding the surveillance testing strategy across campus in order to meet an increasing desire for expanded testing as well as promoting education to the broader student community regarding UConns COV2 strategy (through a new partnership with the newly establishedDxGroupat UConn), Onorato said. We are also considering a more routine pooled sampling approach for our residential student population.

Original post:
UConn faculty reflect on surveillance testing efforts, look to the future - UConn Daily Campus

Notch Therapeutics Strengthens Leadership Team with Appointment of Kamran Alam as CFO and Gregory Block as SVP, Corporate Development – BioSpace

TORONTO, Oct. 19, 2020 /PRNewswire/ --Notch Therapeutics Inc., a cell therapy company with a proprietary platform for generating renewable stem cell-derived T cell therapies for cancer and other immune disorders, announced today the appointment of Kamran Alam as Executive Vice President, Finance and Chief Financial Officer and Gregory Block as Senior Vice President, Corporate Development, effective immediately.

"Adding these experienced leaders to our team underpins our strategy of advancing our pipeline and supporting our partnering initiatives," said David Main, President and Chief Executive Officer of Notch. "Their combined expertise in financial and corporate strategy will augment our deep technical team as we advance our proprietary platform that enables the development of highly consistent T cell therapies manufactured at industrial scale and lower cost. We look forward to their contributions as members of our executive team."

Kamran Alam, Executive Vice President, Finance and Chief Financial OfficerKamran Alam brings to Notch more than 20 years of global corporate finance and business development leadership experience. He joins Notch from Neoleukin Therapeutics, where he served as Interim Chief Financial Officer following Neoleukin's merger in 2018 with Aquinox Pharmaceuticals. Previously, in his role as Chief Financial Officer and Vice President, Finance at Aquinox, Mr. Alam provided finance leadership for the company's IPO on the NASDAQ stock exchange in 2014. Prior to his tenure with Aquinox, Mr. Alam held senior roles in business development for a number of biotechnology and pharmaceutical companies. Mr. Alam is a Chartered Professional Accountant. He holds a B.Sc. in Cell Biology and Genetics from the University of British Columbia and an M.B.A. in International Business and Strategy from the University of Victoria.

Gregory Block, Ph.D., Senior Vice President, Corporate DevelopmentGregory Block is a seasoned biotechnology executive with more than 10 years of experience in the development and commercialization of novel therapeutic modalities. Prior to his position with Notch, he served as Director of Business Development for Astellas Pharmaceuticals, where he led business development and strategic initiatives for regenerative medicine and cell therapy immune oncology. Dr. Block joined Astellas via the company's 2018 acquisition of Universal Cells Inc., where he was instrumental in company-building and business development. Dr. Block holds a Ph.D. in Molecular Biology from Tulane University and completed a fellowship at the University of Washington.

About Notch Therapeutics (www.notchtx.com)Notch Therapeutics is a cell therapy company that has unlocked the ability to produce T cells and other cells from any source of stem cells. At the core of the Notch technology is the Engineered Thymic Niche (ETN) platform, which enables precision control of cell fate during the differentiation and expansion of stem cells. The ETN is the first technology that can reliably generate T-cells from iPSC-derived progenitor cells using fully defined, non-xenogenic reagents at industrial scale. By leveraging the ETN platform, Notch is positioned to design and deliver the next generation of T cell therapeutics that are specifically engineered to address the underlying biology of complex disease systems. The technology was invented in the laboratories of Juan-Carlos Ziga-Pflcker, Ph.D. at Sunnybrook Research Institute and Peter Zandstra, Ph.D., FRSC at the University of Toronto. Notch was founded by these two institutions, in conjunction with MaRS Innovation (now Toronto Innovation Acceleration Partners) and the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto.

Contact:Mary MoynihanM2Friend Biocommunications802-951-9600mary@m2friend.com

View original content:http://www.prnewswire.com/news-releases/notch-therapeutics-strengthens-leadership-team-with-appointment-of-kamran-alam-as-cfo-and-gregory-block-as-svp-corporate-development-301154463.html

SOURCE Notch Therapeutics

Read the original post:
Notch Therapeutics Strengthens Leadership Team with Appointment of Kamran Alam as CFO and Gregory Block as SVP, Corporate Development - BioSpace

Retinal Cell Biology Market Research Report, Revenue, Manufactures and Forecast Until 2028 – The Think Curiouser

Future Market Insights (FMI) presents its new, comprehensive study on the Global Retinal Cell Biology Market spanning from 2020 to 2022. Researches at FMI have no left no stone unturned in bestowing readers a comprehensive view of the market, by studying the drivers, trends, challenges, and restraints. Backed by historical data and projected data, the report breaks down the vast study into numerous geographies and end-use segments, among others to condense the research.

Analysts at FMI have employed in-depth analysis to offer a lucid understanding of the market and the factors shaping its growth trajectory. Ranging from macro socio-economic factors to micro geography-specific trends, the research has taken into consideration every facet that is likely to play a vital role in the growth of the market in the years to come. Presenting a plethora of valuable information, the report will serve as an effective tool, guiding the market players in making fruitful decisions in the forthcoming years.

To ease the understanding of the reader, the report uses CAGR to represent the growth of the market and individual segments. According to the study, the global Retinal Cell Biology market is forecasted to grow at a CAGR of ~11.1% during the assessment period.

Sample of Research Report @https://www.futuremarketinsights.com/reports/sample/rep-gb-8663

Impact of COVID-19 on Retinal Cell Biology Market

The unforeseen outbreak of COVID-19, which swiftly metamorphosed into the pandemic of unexpected proportions, has shifted the worlds focus towards the healthcare sector. National governments are closely working with healthcare institutions and pharmaceutical companies to provide effective treatment to patients suffering with the infection. As a result, there has been a reorientation of medical priorities across healthcare institutions with treatment for COVID-19 patients being the utmost priority. This is sure to impact the growth of the Retinal Cell Biology market through the pandemic period.

FMIs report includes a dedicated section expounding both the short-term and long-term impact of the pandemic on the Retinal Cell Biology market. The study is shaped to bolster stakeholders in making the right decisions to mitigate challenges and leverage opportunities through the pandemic.

Why Choose Future Market Insights?

Retinal Cell Biology Market: Segmentation

To simply the gargantuan study, the report is segregated on the basis of different segments.

Based on drug class

Based on indication

By Region:

The aforementioned segments are studied with respect to each individual region, considering the region-specific trends, drivers and restraints.

Request for covid19 Impact Analysis @ https://www.futuremarketinsights.com/checkout/8663

Key Questions Answered in FMIs Retinal Cell Biology Market Report

ABOUT US:

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.

FMIs research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

CONTACT US:

Mr. Abhishek Budholiya

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

MARKET ACCESS DMCC Initiative

For Sales Enquiries:[emailprotected]

For Media Enquiries:[emailprotected]

Original post:
Retinal Cell Biology Market Research Report, Revenue, Manufactures and Forecast Until 2028 - The Think Curiouser

Educational Foundation of Alfred, Inc. welcomes Nixon, Shaloo to board – Hornell Evening Tribune

Staff reports| The Evening Tribune

ALFRED The Educational Foundation of Alfred, Inc., a private foundation representing faculty, staff, and friends of Alfred State College (ASC), recently welcomed Valerie Nixon and Dr. Ashley Shaloo as new board members.

Nixon is an executive vice president emeritus at Alfred State who served the college for more than 30 years before her retirement in 2019. Her roles at ASC included executive vice president, interim college president, vice president for administration and enrollment, vice president for enrollment management, and director of financial aid. Among her honors are the SUNY Chancellors Award for Excellence in Professional Service and the SUNY Financial Aid Professionals William A. Troy Service Award. Before joining Alfred State, she held positions at Alfred University, the Rochester Institute of Technology, and The College at Brockport.

Nixon holds a bachelors degree in business administration from SUNY Fredonia and a Master of Professional Studies degree in community services administration from Alfred University. She resides in Canisteo with her husband, Robert.

Shaloo is an assistant professor in Alfred States Physical and Life Sciences Department. She serves as the program director for the biological science associate degree program, teaches at least 18 credit hours per semester, and is a co-adviser to the Science Society club.

Shaloo holds a doctorate in molecular and cell biology from Uniformed Services University of the Health Sciences and a Bachelor of Science in biology from Georgian Court University. She resides in Alfred Station.

Read the original post:
Educational Foundation of Alfred, Inc. welcomes Nixon, Shaloo to board - Hornell Evening Tribune

Harvard Business School and Harvard’s Department of Stem Cell and Regenerative Biology Receive $25 Million Gift from Chris and Carrie Shumway to…

Harvard Business School (HBS) and Harvards Department of Stem Cell and Regenerative Biology (HSCRB) have received a $25 million gift from Chris and Carrie Shumway (MBA 1993) to fund programs promoting leadership in life sciences, including the MS/MBA Biotechnology: Life Sciences, a joint degree offered by HBS and the Graduate School of Arts and Sciences and Harvard Medical School through HSCRB. The gift will help bridge the worlds of business and science by fostering an environment of collaboration and innovation at HBS and across Harvard, supporting work on pathbreaking research and educating a new generation of leaders in the life sciences. The gift will provide support for curriculum development and programming, faculty research, and student financial aid.

Every day we are contending with the challenges posed by a worldwide pandemic and seeing firsthand the importance of strong connections between the lab bench and the private sector, said Harvard President Larry Bacow. The Shumways have given us the opportunity to think deeply about how we train leaders at this intersection that will only grow in complexity and importance. We are grateful for their foresight and their exceptional generosity.

This gift will provide the University with the resources to support future leaders in life sciences, dramatically increase innovation and the commercialization of new discoveries, and efficiently and quickly take transformative discoveries from the laboratory to patients and the marketplace, said HBS Dean Nitin Nohria. The world needs more business leaders working at the intersection of science and society, with deep understanding of not only biotechnology and life sciences, but the management skills needed to help these important companies thrive.

To meet this need, the MS/MBA Biotechnology: Life Sciences Program, welcomed its first cohort of students this past August. In supporting financial aid that will cover the incremental costs of the MS/MBA program for these students, this gift will enable Harvard to attract and support outstanding students who already have experience and knowledge in life sciences. To recognize this support, the students in this program will be known as Shumway Fellows and this program will prepare them to take on leadership roles in biotechnology and life sciences organizations.

The program builds upon students existing biotech and life sciences knowledge and equips them with the latest business and scientific insights. This empowers them to launch, grow, and lead transformative organizations that will advance new drug discoveries or therapeutics. Students in the program study general management at HBS and life-sciences at HSCRB, which is a joint department of Harvards Faculty of Arts and Sciences (FAS) and Harvard Medical School (HMS). They benefit from the leadership of program co-chairs Amitabh Chandra (Henry and Allison McCance Professor of Business Administration at HBS and the Ethel Zimmerman Winer Professor of Public Policy and Director of Health Policy Research at the Harvard Kennedy School of Government) Mark Fishman (Professor of Stem Cell and Regenerative Biology at Harvard University and Chief of Pathways Consult Service at Massachusetts General Hospital), and Douglas Melton (Xander University Professor at Harvard University and Co-Director of the Harvard Stem Cell Institute).

The MS/MBA program is a collaborative effort from several schools across Harvard to fill a unique need we see in the industry, said Emma Dench, dean of GSAS. The program provides students with the opportunity to become conversant in both biomedical science and business, and this generous gift will help to ensure that we can prepare them to lead in the rapidly growing life sciences fields.

The future of life sciences innovation will increasingly require deep scientific knowledge coupled with targeted business acumen, said George Q. Daley, dean of HMS. With this joint degree, Harvard will be uniquely positioned to educate students to lead at this nexus.

Sometimes it is at the intersection of disciplines where we find opportunities to ask new questions that have the potential to completely change the way we think about a problem, said Edgerley Family Dean of the Faculty of Arts and Sciences Claudine Gay. This gift will enable Harvard to attract and support talented scholars in the life sciences and equip them with the tools they need to work at the interface of business and life sciences, asking the new questions that promote discovery and innovation in this important area.

Harvard has created an exceptional ecosystem that can develop and cultivate talented professionals across medicine, business and life sciences who are best positioned to tackle the worlds biggest global health challenges today and in the future, said Chris Shumway, managing partner and founder of Shumway Capital. As Harvard is geographically situated at the epicenter of the life sciences community with access to some of the worlds leading hospitals, pharma and biotechnology companies, we believe a tremendous opportunity exists to foster cross-pollination of ideas by marshalling the resources of Harvard and connecting with industry leaders to quickly understand and solve problems.

The gift will also support HBS as it engages and works closely with entrepreneurs and practitioners in the field on the creation of new research and the development of executive education training to serve their unique needs.

The acceleration of global health issues, including the current pandemic, demonstrates the need for entrepreneurial thinking, Chris Shumway added. Leaders born out of these programs will be equipped to drive organizations at the forefront of groundbreaking discoveries with the mindset needed to solve complex problems worldwide.

As an entrepreneur and Managing Partner of Shumway Capital, Chris Shumway has invested in, advised, and built growth businesses for over 25 years, including in biotechnology and life sciences. The Shumways are long-time supporters and advocates for philanthropic initiatives. As strong proponents of education reform, they established the Shumway Foundation with the primary goal of helping to break the cycle of poverty through better opportunities in education. The Shumway Foundation also actively supports other results-based non-profit organizations.

Read this article:
Harvard Business School and Harvard's Department of Stem Cell and Regenerative Biology Receive $25 Million Gift from Chris and Carrie Shumway to...

Reaction Biology and 4HF Biotec Announce Bioinformatic Cell Service – BioSpace

FREIBURG, Germany, Oct. 19, 2020 /PRNewswire/ --Reaction Biology Corp., a drug discovery CRO with offices in Pennsylvania and Germany, and 4HF Biotec GmbH, a bioinformatics firm based in Freiburg, Germany, today announced a new cell-based service offering. The new service combines Reaction Biology's ProLiFiler cell assay service with 4HF's Biomarker Analysis and MOA Finder tools. 4HF Biotech has built a comprehensive database including data from more than 1,800 preclinical samples comprising multiple cancer datasets that are integrated into a single platform for visualization and statistical analysis. The data relevant for the Biomarker Analysis Tool are mutations (whole-exome sequencing), gene copy numbers, and gene expression data. The MoA Finder tool aims to identify the mode of action (MoA) of the test compound by comparing the sensitivity profile of the drug candidate to that of known drugs.

Results of Reaction Biology's 140 cell line assay will be put through both tools of Biomarker Analysis and MOA Finder to give customers a comprehensive understanding of their drug candidates. For Biomarker Analysis, a correlation analysis is performed for each cell line to determine the correlation of the drug sensitivity to each gene with regard to the expression level, mutation status, and/or somatic copy number. For MoA Finder, the test compound's sensitivity profile is compared to more than 700 drugs for which the Mode of Action is known.

"This will give our customers deep insight into the likely genetic response to the drug candidates they test with us," said Dr. Haiching Ma, Chief Science Officer of Reaction Biology. "A cell profile study can shine a spotlight on what a compound is doing, but combining that with 4HF's bioinformatics creates a roadmap for our customers' further development."

"Seeing the phenotypic effects of a compound is only half the information required for an informed drug discovery decision," said Dr. Vincent Vuaroqueaux, CSO of 4HF. "Our bioinformatic approach to building an oncological drug response profile will provide the other half. The Reaction Biology platform is the perfect application for our data analytics."

The service will be performed at Reaction Biology's labs, collaborating with 4HF for analysis. Both companies' labs are in Freiburg.

About Reaction Biology: Founded in 2001, the company provides a full suite of preclinical drug discovery services to over 1600 customers worldwide. It maintains lab facilities in Malvern PA and Freiburg Germany, with sales offices in the US, Germany, France, the UK, Japan, and China. http://www.reactionbiology.com

About 4HF Biotec: 4HF Biotec GmbH was founded in June 2015 by Prof. Dr. H.H. Fiebig. The company is specialized in bioinformatics and data analytics for discovery of innovative therapies to treat cancers. Its team includes experts in medical oncology, anticancer drug evaluation, genomics and bioinformatics. http://www.4hfbiotec.com

Contacts:

Dr. Haiching Ma, CSO Reaction Biology Corporation, +1 610 722 0247, 256966@email4pr.comDr. Vincent Vuaroqueaux, CSO 4HF Biotec GmbH, +49 761 708893-10, 256966@email4pr.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/reaction-biology-and-4hf-biotec-announce-bioinformatic-cell-service-301154559.html

SOURCE Reaction Biology Corporation

See the original post here:
Reaction Biology and 4HF Biotec Announce Bioinformatic Cell Service - BioSpace

Phosplatin Therapeutics Announces Presentation of Research into PT-112 Mechanism of Action at the 32nd EORTC-NCI-AACR Virtual Symposium – BioSpace

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that data revealing novel mechanistic attributes of its lead candidate PT-112, an immunogenic cell death (ICD) inducer under Phase 2 development, will be presented at the 32nd Symposium of the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) taking place virtually from October 24-25.

Title:

PT-112, A First-In-Class Pyrophosphate-Platinum Conjugate, Selectively Targets Highly Glycolytic Tumor Cells (catalog number 188)

Abstract availability:

Saturday, October 24, 2020 on EORTC-NCI-AACR symposium site and on the Phosplatin Therapeutics web site

Session:

New Drugs Poster Session (code 380)

Lead Author:

A. Anel, University of Zaragoza /Aragn Health Research Institute, Biochemistry and Molecular and Cell Biology, Zaragoza, Spain

Building upon prior publication of the ICD effects of PT-112, the body of work to be presented is part of an effort to understand the metabolic pathways and cellular targets affected by PT-112 upstream of ICD initiation. "The data to be reported at the 32nd EORTC-NCI-AACR Virtual Symposium advance the body of knowledge around PT-112's pleiotropic mechanism of action and provide valuable information on further potential clinical applications of PT-112. As we continue our clinical study of this unique compound in patients with challenging cancers, such insights are important," said Robert Fallon, co-founder and chief executive officer, Phosplatin Therapeutics. "We are pleased to co-present this body of work under our fruitful collaboration with the Anel lab at the University of Zaragoza, Spain."

About PT-112

PT-112 is a novel small molecule conjugate of pyrophosphate that possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs) that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor microenvironment. PT-112 represents the best-in-class small molecule inducer of this immunological form of cancer cell death and is currently under Phase II development. The rst in-human study of PT-112 demonstrated an attractive safety prole and evidence of long-lasting responses among heavily pre-treated patients and won "Best Poster" within the Developmental Therapeutics category at the ESMO 2018 Annual Congress. The novelty of PT-112's pyrophosphate moiety also results in osteotropism, or the propensity of the drug to reach the mineralized bone. This property is of interest in cancer types that originate in or metastasize to the bone. The combination Phase Ib study of PT-112 with PD-L1 checkpoint inhibitor avelumab in solid tumors was reported in an oral presentation at the ESMO 2020 Virtual Congress.

About Phosplatin Therapeutics

Phosplatin Therapeutics is a privately held, clinical stage pharmaceutical company that holds exclusive global license to phosphaplatins, a family of small molecules rationally designed to circumvent the mechanisms of drug resistance and toxicity commonly associated with chemotherapeutic regimens. The company's lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique combination of properties, including immunogenic cell death and osteotropism. Clinical data generated to date across three Phase I studies have demonstrated single-agent anti-cancer activity and an attractive tolerability prole, and two Phase II studies of PT-112 are underway. The company's research and development work to date has spanned fteen countries and been funded by private investors and family investment ofces in the United States, Europe and Asia, along with a sub-license agreement for the development, commercialization and use of PT-112 in Greater China. The company sponsors the ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pzer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada).

CONTACTS:

Phosplatin TherapeuticsTaylor YoungSenior Director of Strategic DevelopmentTel: +1 646 380 2441Email: tyoung@phosplatin.com

Westwicke, an ICR CompanyInvestors:Stephanie CarringtonTel: +1 646 277 1282Email: Stephanie.Carrington@westwicke.com

Media:Mark CorbaeTel: +1 203 682 8288Email: mark.corbae@westwicke.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/phosplatin-therapeutics-announces-presentation-of-research-into-pt-112-mechanism-of-action-at-the-32nd-eortc-nci-aacr-virtual-symposium-301155292.html

SOURCE Phosplatin Therapeutics

Excerpt from:
Phosplatin Therapeutics Announces Presentation of Research into PT-112 Mechanism of Action at the 32nd EORTC-NCI-AACR Virtual Symposium - BioSpace

Anti-age your immune system here’s how to turn back the clock – The Times

As with nearly everything else to do with our bodies, the effectiveness of the immune system declines with age. From our twenties onwards the bodys ability to fight infection decreases at a rate of about 2 to 3 per cent a year, gradually leaving us more susceptible to diseases, says Janet Lord, a professor of immune cell biology and the director of the Institute for Inflammation and Ageing at Birmingham University. But, she says, the speed at which this happens is not unavoidable. Ill health should not be an inevitable part of growing old. By understanding what happens to our immune systems as we age, we can break that link.

Ageing of the immune system is accelerated by the usual baddies, smoking, a sedentary lifestyle,

Read the original here:
Anti-age your immune system here's how to turn back the clock - The Times

Study reports chemical mechanism that boosts enzyme observed in cancer – Newswise

Newswise A new study led by scientists at IUPUI and Indiana University Bloomington is the first to describe a biochemical mechanism that increases the activity of a molecule whose presence is observed in many types of cancer.

The molecule, an enzyme called Pif1helicase, plays a role in many important cellular processes in the body. Tightly regulating this protein is vital to genome stability because too little -- or too much -- activity can influence aging and age-related diseases, primarily cancer. A common cancer therapy, HDAC inhibitors, can also trigger a spike in this enzyme.

"Currently, we're giving people drugs that increase Pif activity without fully knowing how it affects other parts of the cell that play a role in genome stability," said Lata Balakrishnan, an associate professor of biology in the School of Science at IUPUI, who is co-lead author on the study.

"HDAC inhibitors upregulate certain tumor-suppression genes, and therefore are used in combination therapies to treat specific cancers, but when it comes to their impact on other parts of the cell, we're basically operating in the dark."

The study's other lead author is Matthew Bochman, an associate professor in the IU Bloomington College of Arts and Sciences' Department of Molecular and Cellular Biochemistry. Other co-authors are Christopher Sausen and Onyekachi E. Ononye, Ph.D. students in Bochman's and Balakrishnan's labs, respectively, at the time of the study.

The mechanism described in the study is the effect of lysine acetylation on Pif1. Lysine acetylation occurs when a small molecule called an acetyl group binds to lysine, an amino acid used to build common proteins in the body. This action transforms lysine from a positively charged molecule to a neutrally charged molecule. This neutralization can impact protein function, protein stability and protein-protein interaction in cells, among other things.

Helicases are known as the genetic "zippers" of cells because they pull apart DNA for the purpose of genetic replication and repair. They also help maintain telomeres, the structure at the end of chromosomes that shorten as people age.

In the new study, the researchers identified lysine acetylation on Pif1 helicase and showed the addition of the acetyl group increases the protein's activity -- as well as its "unzipping" function. They also found that lysine acetylation changes the shape -- or "conformation" -- of the Pif1 protein. They believe that this shape change increases the amount of Pif1 helicase.

"The dynamic interplay of the addition and removal of the acetyl group on lysine regulates a wide variety of proteins within the cell," Balakrishnan said. "Perturbations to this process can play a role in cancer, aging, inflammatory responses and even addiction-related behaviors."

"As a class, helicases are involved in a lot of processes necessary for genome integrity," Bochman added. "Any significant failure in these processes is generally carcinogenic."

The precise details of lysine acetylation in Pif1, its effect of the enzyme's shape and the resulting impact on helicase activity took nearly five years to observe and report. The study, carried out in parallel on two IU campuses, was made possible by the lead scientists' complementary expertise. As a biochemist who has previously studied lysine acetylation in other proteins, Balakrishnan was able to isolate Pif1 in vitro to observe its response to chemical reactions in a test tube. In contrast, as a geneticist working in yeast as a model organism to study Pif1, Bochman was able to modify cells in vivo to watch reactions play out in a living organism.

"The ability to observe these reactions in a living cell is often more relevant, but it's also a lot messier," Balakrishnan said. "Our experiments were constantly informing each other as to where to go next.

Looking to the future, Bochman said intricate knowledge of cellular processes -- such as lysine acetylation -- will increasingly play a role in personalized therapy.

"If you sequence a patient's tumor, you can fine-tune drugs to target very specific enzymes," he said. "Instead of a drug that broadly affects the whole cell, it will be possible to take a targeted approach that reduces potential side effects. This level of personalization is really the future of cancer biology and cancer medicine."

"Lysine Acetylation Regulates the Activity of Nuclear Pif1" is available online in advance of print in the Journal of Biological Chemistry. A perspective article on the work is also forthcoming in the journal Current Genetics.

This work was supported in part by the National Science Foundation and the American Cancer Society.

IU Research

Indiana University's world-class researchers have driven innovation and creative initiatives that matter for 200 years. From curing testicular cancer to collaborating with NASA to search for life on Mars, IU has earned its reputation as a world-class research institution. Supported by $854 million last year from our partners, IU researchers are building collaborations and uncovering new solutions that improve lives in Indiana and around the globe.

See more here:
Study reports chemical mechanism that boosts enzyme observed in cancer - Newswise

Notch Therapeutics Strengthens Leadership Team with Appointment of Kamran Alam as CFO and Gregory Block as SVP, Corporate Development – PRNewswire

TORONTO, Oct. 19, 2020 /PRNewswire/ --Notch Therapeutics Inc., a cell therapy company with a proprietary platform for generating renewable stem cell-derived T cell therapies for cancer and other immune disorders, announced today the appointment of Kamran Alam as Executive Vice President, Finance and Chief Financial Officer and Gregory Block as Senior Vice President, Corporate Development, effective immediately.

"Adding these experienced leaders to our team underpins our strategy of advancing our pipeline and supporting our partnering initiatives," said David Main, President and Chief Executive Officer of Notch. "Their combined expertise in financial and corporate strategy will augment our deep technical team as we advance our proprietary platform that enables the development of highly consistent T cell therapies manufactured at industrial scale and lower cost. We look forward to their contributions as members of our executive team."

Kamran Alam, Executive Vice President, Finance and Chief Financial OfficerKamran Alam brings to Notch more than 20 years of global corporate finance and business development leadership experience. He joins Notch from Neoleukin Therapeutics, where he served as Interim Chief Financial Officer following Neoleukin's merger in 2018 with Aquinox Pharmaceuticals. Previously, in his role as Chief Financial Officer and Vice President, Finance at Aquinox, Mr. Alam provided finance leadership for the company's IPO on the NASDAQ stock exchange in 2014. Prior to his tenure with Aquinox, Mr. Alam held senior roles in business development for a number of biotechnology and pharmaceutical companies. Mr. Alam is a Chartered Professional Accountant. He holds a B.Sc. in Cell Biology and Genetics from the University of British Columbia and an M.B.A. in International Business and Strategy from the University of Victoria.

Gregory Block, Ph.D., Senior Vice President, Corporate DevelopmentGregory Block is a seasoned biotechnology executive with more than 10 years of experience in the development and commercialization of novel therapeutic modalities. Prior to his position with Notch, he served as Director of Business Development for Astellas Pharmaceuticals, where he led business development and strategic initiatives for regenerative medicine and cell therapy immune oncology. Dr. Block joined Astellas via the company's 2018 acquisition of Universal Cells Inc., where he was instrumental in company-building and business development. Dr. Block holds a Ph.D. in Molecular Biology from Tulane University and completed a fellowship at the University of Washington.

About Notch Therapeutics (www.notchtx.com)Notch Therapeutics is a cell therapy company that has unlocked the ability to produce T cells and other cells from any source of stem cells. At the core of the Notch technology is the Engineered Thymic Niche (ETN) platform, which enables precision control of cell fate during the differentiation and expansion of stem cells. The ETN is the first technology that can reliably generate T-cells from iPSC-derived progenitor cells using fully defined, non-xenogenic reagents at industrial scale. By leveraging the ETN platform, Notch is positioned to design and deliver the next generation of T cell therapeutics that are specifically engineered to address the underlying biology of complex disease systems. The technology was invented in the laboratories of Juan-Carlos Ziga-Pflcker, Ph.D. at Sunnybrook Research Institute and Peter Zandstra, Ph.D., FRSC at the University of Toronto. Notch was founded by these two institutions, in conjunction with MaRS Innovation (now Toronto Innovation Acceleration Partners) and the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto.

Contact:Mary MoynihanM2Friend Biocommunications802-951-9600[emailprotected]

SOURCE Notch Therapeutics

Follow this link:
Notch Therapeutics Strengthens Leadership Team with Appointment of Kamran Alam as CFO and Gregory Block as SVP, Corporate Development - PRNewswire